Volcano Corporation has announced positive study results that demonstrate stent procedures guided by intravascular ultrasound (IVUS) reduce stent thrombosis and myocardial infarction (MI), and improve patient outcomes.

The 3,349-patient prospective ADAPT-DES IVUS sub-study, which included the company’s Eagle Eye Gold IVUS catheters, is a part of the Cardiovascular Research Foundation’s assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The study analysis included assessment of lesion morphology by using both traditional grayscale IVUS and Volcano’s proprietary VH IVUS tissue characterisation technology.

The results demonstrated a 50% reduction in the incidence of stent thrombosis (a blood clot on the surface of a stent) and 33% reduction in MI that began as soon as 30 days post procedure, and continued for 12 months, according to the company.

“The results demonstrated a 50% reduction in the incidence of stent thrombosis (a blood clot on the surface of a stent) and 33% reduction in MI that began as soon as 30 days post procedure, and continued for 12 months.”

Columbia University College of Physicians and Surgeons professor of medicine Dr Gregg Stone said previously, the additive value of IVUS as an independent predictor of stent thrombosis, MI and death had not been assessed in a large-scale study.

“The ADAPT-DES IVUS sub-study provides the strongest evidence to date that use of IVUS to guide optimising placement improves patient outcomes,” Stone said.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Volcano Corporation president and CEO Scott Huennekens said the results at 30 days and 12 months meaningfully advance the field of interventional cardiology, and also have important implications for institutions seeking strategies to improve the quality of care and avoid penalties imposed by the new CMS 30-day readmission policy.

“With the insight our technologies such as IVUS provide, Volcano can help physicians and healthcare institutions answer the growing demand for truly personalized medicine that is appropriate, evidence-based and accountable,” Huennekens said.